ACTON, III; John J.

Patent Applications and Registrations

Patent applications and USPTO patent grants for ACTON, III; John J..The latest application filed is for "1-pyrazolyl, 5-, 6- disubstituted indazole derivatives as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof".

Company Profile

5.13.13

ACTON, III; John J. - Kenilworth NJ US
Acton, III; John J. - Bridgewater NJ
Acton, III; John J. - Cranford NJ

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
1-pyrazolyl, 5-, 6- Disubstituted Indazole Derivatives As Lrrk2 Inhibitors, Pharmaceutical Compositions, And Uses Thereof App 20220259188 - Zhou; Hua ; et al.	2022-08-18
3-(1H-pyrazol-4-yl)pyridine allosteric modulators of the M4 muscarinic acetylcholine receptor Grant 11,339,156 - Acton, III , et al. May 24, 2	2022-05-24
3-(1h-pyrazol-4-yl)pyridine Allosteric Modulators Of The M4 Muscarinic Acetylcholine Receptor App 20210395224 - Acton, III; John J. ; et al.	2021-12-23
N-heteroaryl Indazole Derivatives As Lrrk2 Inhibitors, Pharmaceutical Compositions, And Uses Thereof App 20210395236 - SIMOV; Vladimir ; et al.	2021-12-23
3-(1h-pyrazol-4-yl)pyridine Allosteric Modulators Of The M4 Muscarinic Acetylcholine Receptor App 20210380580 - ACTON, III; John J. ; et al.	2021-12-09
3-(1H-pyrazol-4-yl)pyridine allosteric modulators of the M4 muscarinic acetylcholine receptor Grant 11,149,036 - Acton, III , et al. October 19, 2	2021-10-19
3-(1H-pyrazol-4-yl)pyridine allosteric modulators of the M4 muscarinic acetylcholine receptor Grant 10,933,056 - Acton, III , et al. March 2, 2	2021-03-02
3-(1h-pyrazol-4-yl)pyridine Allosteric Modulators Of The M4 Muscarinic Acetylcholine Receptor App 20200207758 - ACTON, III; John J. ; et al.	2020-07-02
3-(1h-pyrazol-4-yl)pyridine Allosteric Modulators Of The M4 Muscarinic Acetylcholine Receptor App 20200069671 - Acton, III; John J. ; et al.	2020-03-05
3-(1h-pyrazol-4-yl)pyridine Allosteric Modulators Of The M4 Muscarinic Acetylcholine Receptor App 20190000824 - Acton, III; John J. ; et al.	2019-01-03
Indole derivatives useful as anti-diabetic agents Grant 9,650,375 - Acton, III , et al. May 16, 2	2017-05-16
Cyclic amine substituted heterocyclic CETP inhibitors Grant 9,353,101 - Acton, III , et al. May 31, 2	2016-05-31
Novel Indole Derivatives Useful As Anti-diabetic Agents App 20160002224 - Acton, III; John J. ; et al.	2016-01-07
Cyclic Amine Substituted Heterocyclic Cetp Inhibitors App 20150111866 - Acton, III; John J. ; et al.	2015-04-23
Indoles having anti-diabetic activity Grant 7,393,960 - Acton, III , et al. July 1, 2	2008-07-01
Indoles having anti-diabetic activity Grant 7,345,085 - Acton, III , et al. March 18, 2	2008-03-18
Indoles having anti-diabetic activity Grant 7,186,746 - Acton, III , et al. March 6, 2	2007-03-06
Indoles having anti-diabetic activity App 20050277685 - Acton III, John J. ; et al.	2005-12-15
Acyl sulfamides for treatment of obesity, diabetes and lipid disorders Grant 6,852,738 - Jones , et al. February 8, 2	2005-02-08
Acyl sulfamides for treatment of obesity, diabetes and lipid disorders App 20040073037 - Jones, A. Brian ; et al.	2004-04-15
N-substituted indoles useful in the treatment of diabetes Grant 6,525,083 - Acton, III , et al. February 25, 2	2003-02-25
Pseudopeptide lactam inhibitors of peptide binding to MHC class II proteins Grant 5,719,296 - Acton, III , et al. February 17, 1	1998-02-17

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.